JP2021532193A5 - - Google Patents

Info

Publication number
JP2021532193A5
JP2021532193A5 JP2021529250A JP2021529250A JP2021532193A5 JP 2021532193 A5 JP2021532193 A5 JP 2021532193A5 JP 2021529250 A JP2021529250 A JP 2021529250A JP 2021529250 A JP2021529250 A JP 2021529250A JP 2021532193 A5 JP2021532193 A5 JP 2021532193A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
solid dispersion
leukemia
composition according
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/044853 external-priority patent/WO2020028778A1/en
Publication of JP2021532193A publication Critical patent/JP2021532193A/ja
Publication of JP2021532193A5 publication Critical patent/JP2021532193A5/ja
Pending legal-status Critical Current

Links

JP2021529250A 2018-08-03 2019-08-02 生物学的に利用可能な経口剤形 Pending JP2021532193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714182P 2018-08-03 2018-08-03
US62/714,182 2018-08-03
PCT/US2019/044853 WO2020028778A1 (en) 2018-08-03 2019-08-02 Bioavailable oral dosage forms

Publications (2)

Publication Number Publication Date
JP2021532193A JP2021532193A (ja) 2021-11-25
JP2021532193A5 true JP2021532193A5 (cg-RX-API-DMAC7.html) 2022-10-07

Family

ID=67766269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529250A Pending JP2021532193A (ja) 2018-08-03 2019-08-02 生物学的に利用可能な経口剤形

Country Status (23)

Country Link
US (1) US20210205225A1 (cg-RX-API-DMAC7.html)
EP (1) EP3829544A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021532193A (cg-RX-API-DMAC7.html)
KR (1) KR20210041589A (cg-RX-API-DMAC7.html)
CN (1) CN112752570A (cg-RX-API-DMAC7.html)
AR (1) AR115913A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019316036A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001859A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107737A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000271A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021001979A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210093A (cg-RX-API-DMAC7.html)
EA (1) EA202190429A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21011795A (cg-RX-API-DMAC7.html)
IL (1) IL280471A (cg-RX-API-DMAC7.html)
MX (1) MX2021001364A (cg-RX-API-DMAC7.html)
NI (1) NI202100006A (cg-RX-API-DMAC7.html)
PE (1) PE20211410A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550237A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100984VA (cg-RX-API-DMAC7.html)
TN (1) TN2021000021A1 (cg-RX-API-DMAC7.html)
TW (1) TW202019414A (cg-RX-API-DMAC7.html)
WO (1) WO2020028778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
WO2023130070A2 (en) 2021-12-31 2023-07-06 Ptc Therapeutics, Inc. Carboline compounds and use thereof
US20220151938A1 (en) * 2022-01-28 2022-05-19 Ptc Therapeutics, Inc. Tablet for use in treating huntington's disease and method of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249799A1 (en) 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7601840B2 (en) 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
US20180344646A1 (en) * 2015-11-25 2018-12-06 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms

Similar Documents

Publication Publication Date Title
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
KR101489401B1 (ko) 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
CN107260695A (zh) 硝唑尼特的控制释放药物剂型
SK285300B6 (sk) Farmaceutická formulácia obsahujúca množinu liekových podjednotiek a spôsob jej výroby
JP2013533241A (ja) 食物効果が減少した制御放出組成物
JP7652787B2 (ja) ベンズイミダゾール誘導体化合物を含有する医薬組成物
JP2022535893A5 (cg-RX-API-DMAC7.html)
US11135159B2 (en) Optimized high-dose mesalazine-containing tablet
WO2013132208A1 (en) Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
CN105338970B (zh) 包含他达拉非和坦洛新的药物胶囊复合制剂
WO2021129735A1 (zh) 一种固体制剂及其制备方法和用途
US20200253880A1 (en) Sustained release compositions of 4-aminopyridine
JP6902043B2 (ja) フマル酸ジメチルを含む医薬ビーズ製剤
CN108012526A (zh) 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法
JP2019532960A (ja) エソメプラゾール含有複合カプセル剤及びその製造方法
TWI651084B (zh) 包含異菸鹼醯胺(isoniazid)顆粒及利福噴丁(rifapentine)顆粒之包衣錠劑型態的抗肺結核穩定醫藥組合物及其製備方法
US20080118554A1 (en) Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
JP2018123140A (ja) 活性成分(i)含有組成物及びその製造方法
CA3064006A1 (en) Modified release pharmaceutical compositions of huperzine and methods of using the same
CN101411702A (zh) 盐酸奈福泮萘普生钠复方缓释制剂及其制备方法
CN101909625A (zh) 新型抗逆转录病毒组合
WO2015197535A1 (en) Modified release pharmaceutical compositions of sofosbuvir and ribavirin
JP5919173B2 (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
KR20160025075A (ko) 구강내 속붕해 필름 조성물 및 그 제조방법
KR20160081646A (ko) 멜라토닌 및 설트랄린을 포함하는 경구용 복합정제